Ignite Creation Date:
2024-05-05 @ 4:43 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00292435
Status:
COMPLETED
Last Update Posted:
2013-10-29
First Post:
2006-02-15
Brief Title:
Efficacy and Tolerability CVI A 12-week Double-blind Randomised Placebo-controlled Multicentre Trial CVI
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
A 12-week Double-blind Randomised Placebo-controlled Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax Film-coated Tablets 360 mgDay Orally in Male and Female Patients Suffering From Chronic Venous Insufficiency
Status:
COMPLETED
Status Verified Date:
2013-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine efficacy and tolerability of Antistax 360 mg tablets in chronic venous insufficiency linked to edema swelling and subjective symptoms
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None